JP2013503148A5 - - Google Patents

Download PDF

Info

Publication number
JP2013503148A5
JP2013503148A5 JP2012526141A JP2012526141A JP2013503148A5 JP 2013503148 A5 JP2013503148 A5 JP 2013503148A5 JP 2012526141 A JP2012526141 A JP 2012526141A JP 2012526141 A JP2012526141 A JP 2012526141A JP 2013503148 A5 JP2013503148 A5 JP 2013503148A5
Authority
JP
Japan
Prior art keywords
composition
oligonucleotide
polymer
aluminum salt
immunogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012526141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013503148A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/002259 external-priority patent/WO2011024071A1/en
Publication of JP2013503148A publication Critical patent/JP2013503148A/ja
Publication of JP2013503148A5 publication Critical patent/JP2013503148A5/ja
Ceased legal-status Critical Current

Links

JP2012526141A 2009-08-27 2010-08-27 アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント Ceased JP2013503148A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23759509P 2009-08-27 2009-08-27
US61/237,595 2009-08-27
PCT/IB2010/002259 WO2011024071A1 (en) 2009-08-27 2010-08-27 Adjuvant comprising aluminium, oligonucleotide and polycation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015236813A Division JP2016034980A (ja) 2009-08-27 2015-12-03 アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント

Publications (2)

Publication Number Publication Date
JP2013503148A JP2013503148A (ja) 2013-01-31
JP2013503148A5 true JP2013503148A5 (enExample) 2013-07-25

Family

ID=43428549

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012526141A Ceased JP2013503148A (ja) 2009-08-27 2010-08-27 アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント
JP2015236813A Pending JP2016034980A (ja) 2009-08-27 2015-12-03 アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015236813A Pending JP2016034980A (ja) 2009-08-27 2015-12-03 アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント

Country Status (9)

Country Link
US (1) US8858958B2 (enExample)
EP (1) EP2470205A1 (enExample)
JP (2) JP2013503148A (enExample)
CN (1) CN102740882A (enExample)
AU (1) AU2010288239B2 (enExample)
BR (1) BR112012004276A2 (enExample)
CA (1) CA2772103A1 (enExample)
NZ (1) NZ598459A (enExample)
WO (1) WO2011024071A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591768A (en) * 2008-09-18 2012-11-30 Novartis Ag Vaccine adjuvant combinations
HK1205138A1 (en) 2012-07-27 2015-12-11 Institut National De La Santé Et De La Recherche Médicale (Inserm) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
CN113321704B (zh) * 2014-08-04 2026-05-12 肿瘤疗法科学股份有限公司 Cdca1衍生的肽和含有它们的疫苗
CN112138155B (zh) * 2019-06-28 2022-04-12 怡道生物科技(苏州)有限公司 一种复合佐剂系统及制备该佐剂的方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
EP0967279B1 (en) 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori cytotoxin useful for vaccines and diagnostics
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
DE69529219T2 (de) 1994-07-01 2003-11-06 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Helicobacter proteine und impstoffe
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
CN1285608C (zh) * 1995-09-22 2006-11-22 康诺特实验室有限公司 副流感病毒糖蛋白和疫苗
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998053851A1 (en) 1997-05-28 1998-12-03 University Of Iowa Research Foundation Laft mutants of pathogenic gram-negative bacteria
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
EP0991761B1 (en) 1997-08-21 2008-01-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
EP2261347A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
CA2347849C (en) 1998-10-22 2013-06-25 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
PT1127137E (pt) 1998-11-03 2007-12-28 Staat Nl Verteg Door Min Welzi Lps com toxicidade reduzida a partir de bactérias gramnegativas modificadas geneticamente
CA2372235A1 (en) 1999-04-30 2000-11-09 Rino Rappuoli Conserved neisserial antigens
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
EP1234039A2 (en) 1999-11-29 2002-08-28 Chiron Spa 85kDa NEISSERIAL ANTIGEN
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
MXPA02007184A (es) 2000-01-25 2004-02-26 Univ Queensland Proteinas que comprenden regiones conservadas de antigenos de superficie nhha de neisseria meningitidis.
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
WO2001093905A1 (en) 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Immunostimulatory oligodeoxynucleotides
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
KR20030024811A (ko) 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
EP1409013B1 (en) * 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP2168596B1 (en) 2001-12-12 2012-05-23 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
ES2320334T3 (es) 2002-02-22 2009-05-21 National Research Council Of Canada Uso de analogos de acidos grasos para el tratamiento y/o prevencion de enfermedades proliferativas de la piel.
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
CA2493124C (en) 2002-08-02 2014-04-29 Glaxosmithkline Biologicals S.A. Vaccine
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CN1809380B (zh) 2002-10-11 2010-05-12 启龙有限公司 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ES2562456T3 (es) * 2003-03-24 2016-03-04 Valneva Austria Gmbh Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
CN100355453C (zh) * 2003-03-24 2007-12-19 英特塞尔股份公司 改进的疫苗
CA2526106A1 (en) 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
BRPI0508365A (pt) 2004-03-02 2007-07-24 Chiron Corp composições imunogênicas para chlamydia pneumoniae
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
LT2682126T (lt) 2005-01-27 2017-02-27 Children`s Hospital & Research Center at Oakland Gna1870 pagrindu gaminamos pūslelių pavidalo vakcinos, skirtos plataus spektro apsaugai nuo neisseria meningitidis sukeltų ligų
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 尿路病原性菌株由来の抗原
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
US8133973B2 (en) 2005-05-12 2012-03-13 Novartis Vaccines And Diagnostics, S.R.L. Immunogenic compositions for Chlamydia trachomatis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US8481057B2 (en) 2005-12-22 2013-07-09 Novartis Vaccines & Diagnostics Srl Chlamydial antigens
WO2007071786A2 (en) * 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
DE602007003596D1 (de) 2006-06-12 2010-01-14 Glaxosmithkline Biolog Sa Impfstoff
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
WO2009077854A2 (en) 2007-11-26 2009-06-25 Novartis Ag Adjuvanted glucans
US8685654B2 (en) 2007-12-24 2014-04-01 Novartis Ag Assays for adsorbed influenza vaccines
EP2886551A3 (en) 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides
ITMI20081249A1 (it) 2008-07-09 2010-01-09 Novartis Vaccines & Diagnostic Immunogeni di escherichia coli con solubilità migliorata.
NZ591768A (en) 2008-09-18 2012-11-30 Novartis Ag Vaccine adjuvant combinations

Similar Documents

Publication Publication Date Title
JP6101330B2 (ja) アジュバント添加した髄膜炎菌h因子結合タンパク質
CN110520154B (zh) 多价肺炎链球菌疫苗组合物
JP5344558B2 (ja) カチオン性ナノゲルを用いる粘膜ワクチン
WO2017143024A2 (en) Pathogen vaccines and methods of producing and using the same
JP2013522287A5 (enExample)
CN104093418A (zh) 金黄色葡萄球菌抗原的含佐剂制剂
JP2013501071A5 (enExample)
US12569558B2 (en) Composite adjuvant system and method for preparing adjuvant
EP4464658A2 (en) Aluminum nanocrystal delivery system, and self-assembled particle adjuvant vaccine based on binding of aluminum nanocrystal delivery system and vaccine antigen molecule
JP2010508276A5 (enExample)
WO2023131356A2 (zh) 四氧化三锰颗粒在制备疫苗佐剂中的应用
Liao et al. Carbopol dispersed PAA-modified UIO-66 with high colloidal stability as a combination nano-adjuvant boosts immune response and protection against pseudorabies virus in mice and pigs
CN102716474B (zh) 蛋白Rh054_01780在抗黑龙江立克次体的免疫保护中的应用
JP2016034980A (ja) アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント
EP2221050A1 (en) Use of microparticles for vaccines and the release of biologically active molecules
US20140248310A1 (en) Cationic metal oxides for use as vaccine adjuvants
Rosales-Mendoza et al. Silica-based mucosal nanovaccines
JP4711964B2 (ja) ワクチンのアジュバントとしてリン酸鉄を含むワクチン組成物
Ohta Cholesteryl Pullulan Nanoparticles-Encapsulated TNF-a: An Effective Mucosal Vaccine Adjuvant Against
RU2779622C9 (ru) Комплекс для усиления иммунного ответа
RU2779622C2 (ru) Комплекс для усиления иммунного ответа
Herbert et al. COORDINATION POLYMER MATRIXES INTENSIFY IMMUNITY AGAINST BLADDER INFECTION
HK40011275B (zh) 多价肺炎链球菌疫苗组合物
AU2013202541A1 (en) Adjuvant comprising aluminium, oligonucleotide and polycation
HK40011275A (en) Polyvalent streptococcus pneumoniae vaccine composition